Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- 11 Phase 1 Trials in Alzheimer’s Disease Drug Development
- 12 The Importance of Phase 2 in Drug Development for Alzheimer’s Disease
- 13 Alzheimer’s Disease Drug Development in Pharmaceutical Companies
- 14 Trial Site Infrastructure and Management: Importance to Alzheimer’s Disease Drug Development
- 15 ATRI and ACTC: Academic Programs to Accelerate Alzheimer’s Disease Drug Development
- 16 The European Prevention of Alzheimer’s Disease Program: A Public–Private Partnership to Facilitate the Secondary Prevention of Alzheimer’s Disease Dementia
- 17 The Global Alzheimer’s Platform Foundation®: Delivering New Medicines Faster by Accelerating Clinical Trials
- 18 Clinical Trial Development in Frontotemporal Lobar Degeneration
- 19 Statistical Considerations in the Design and Analysis of Alzheimer’s Disease Clinical Trials
- 20 Alzheimer’s Disease Trial Recruitment and Diversifying Trial Populations
- 21 The Role of Online Registries in Accelerating Alzheimer’s Disease Drug Development
- 22 Data Safety Monitoring Boards in Alzheimer’s Disease Trials
- 23 Globalization of Alzheimer’s Disease Clinical Trials
- 24 The Use and Development of Clinical Measures of Alzheimer’s Disease Trials
- 25 Tele-Trials, Remote Monitoring, and Trial Technology for Alzheimer’s Disease Clinical Trials
- 26 Expanded Access and Compassionate Use in Alzheimer’s Disease Drug Development
- 27 The Role of the Contract Research Organization in Alzheimer’s Disease: The Vital Link in the Clinical Drug-Development Program
- 28 The Role of Regulatory Agencies in Alzheimer’s Disease Drug Development
- 29 Alzheimer’s Disease Clinical Trial Study Partners
- 30 From Trials to Practice: Are We Ready for a Disease-Modifying Treatment?
- 31 Best Practices for Clinical Trials during COVID-19
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- Index
- References
25 - Tele-Trials, Remote Monitoring, and Trial Technology for Alzheimer’s Disease Clinical Trials
from Section 3 - Alzheimer’s Disease Clinical Trials
Published online by Cambridge University Press: 03 March 2022
Book contents
- Alzheimer’s Disease Drug Development
- Alzheimer’s Disease Drug Development
- Copyright page
- Dedication
- Contents
- Contributors
- Foreword
- Acknowledgments
- Section 1 Advancing Alzheimer’s Disease Therapies in a Collaborative Science Ecosystem
- Section 2 Non-clinical Assessment of Alzheimer’s Disease Candidate Drugs
- Section 3 Alzheimer’s Disease Clinical Trials
- 11 Phase 1 Trials in Alzheimer’s Disease Drug Development
- 12 The Importance of Phase 2 in Drug Development for Alzheimer’s Disease
- 13 Alzheimer’s Disease Drug Development in Pharmaceutical Companies
- 14 Trial Site Infrastructure and Management: Importance to Alzheimer’s Disease Drug Development
- 15 ATRI and ACTC: Academic Programs to Accelerate Alzheimer’s Disease Drug Development
- 16 The European Prevention of Alzheimer’s Disease Program: A Public–Private Partnership to Facilitate the Secondary Prevention of Alzheimer’s Disease Dementia
- 17 The Global Alzheimer’s Platform Foundation®: Delivering New Medicines Faster by Accelerating Clinical Trials
- 18 Clinical Trial Development in Frontotemporal Lobar Degeneration
- 19 Statistical Considerations in the Design and Analysis of Alzheimer’s Disease Clinical Trials
- 20 Alzheimer’s Disease Trial Recruitment and Diversifying Trial Populations
- 21 The Role of Online Registries in Accelerating Alzheimer’s Disease Drug Development
- 22 Data Safety Monitoring Boards in Alzheimer’s Disease Trials
- 23 Globalization of Alzheimer’s Disease Clinical Trials
- 24 The Use and Development of Clinical Measures of Alzheimer’s Disease Trials
- 25 Tele-Trials, Remote Monitoring, and Trial Technology for Alzheimer’s Disease Clinical Trials
- 26 Expanded Access and Compassionate Use in Alzheimer’s Disease Drug Development
- 27 The Role of the Contract Research Organization in Alzheimer’s Disease: The Vital Link in the Clinical Drug-Development Program
- 28 The Role of Regulatory Agencies in Alzheimer’s Disease Drug Development
- 29 Alzheimer’s Disease Clinical Trial Study Partners
- 30 From Trials to Practice: Are We Ready for a Disease-Modifying Treatment?
- 31 Best Practices for Clinical Trials during COVID-19
- Section 4 Imaging and Biomarker Development in Alzheimer’s Disease Drug Discovery
- Section 5 Academic Drug-Development Programs
- Section 6 Public–Private Partnerships in Alzheimer’s Disease Drug Development
- Section 7 Funding and Financing Alzheimer’s Disease Drug Development
- Index
- References
Summary
Digital technologies show great promise for moving clinical trials from using in-person approaches that have perpetuated long drug trial timelines, biased sampling and high costs. A review of the current state, however, reveals that technology use has been largely limited to replicating known methods and/or applied to small study samples. Full realization of the potential will require significant investment in validating digital signals into novel metrics fueled by advanced computational methods. These steps, however, will require regulatory guidance, as well as considerations regarding data security and future proofing against rapid technology obsolescence. Despite these challenges, the end-to-end virtual clinical trial is possible today.
- Type
- Chapter
- Information
- Alzheimer's Disease Drug DevelopmentResearch and Development Ecosystem, pp. 292 - 300Publisher: Cambridge University PressPrint publication year: 2022
References
Food and Drug Administration. Digital Health Innovation Action Plan. Available at: www.fda.gov/media/106331/download (accessed 2018).Google Scholar
Food and Drug Administration. Software as a medical device (SAMD): clinical evaluation. Available at: www.fda.gov/regulatory-information/search-fda-guidance-documents/software-medical-device-samd-clinical-evaluation (accessed 2017).Google Scholar
FDA–NIH Biomarker Working Group. BEST (Biomarkers, Endpoints, and Other Tools) Resource. Silver Spring, MD and Bethesda, MD: Food and Drug Administration and National Institutes of Health; 2016.Google Scholar
Chinner, A, Blane, J, Lancaster, C, Hinds, C, Koychev, I. Digital technologies for the assessment of cognition: a clinical review. Evid-Based Ment Health 2018; 21: 67–71.CrossRefGoogle ScholarPubMed
Koo, BM, Vizer, LM. Mobile technology for cognitive assessment of older adults: a scoping review. Innov Aging 2018; 3: igy038.Google Scholar
Lussier, M, Lavoie, M, Giroux, S, et al. Early detection of mild cognitive impairment with in-home monitoring sensor technologies using functional measures: a systematic review. IEEE J Biomed Health Inform 2019; 23: 838–47.Google Scholar
Thabtah, F, Mampusti, E, Peebles, D, Herradura, R, Varghese, J. A mobile-based screening system for data analyses of early dementia traits detection. J Med Syst 2019; 44: 24.Google Scholar
Piau, A, Wild, K, Mattek, N, Kaye, J. Current state of digital biomarker technologies for real-life, home-based monitoring of cognitive function for mild cognitive impairment to mild Alzheimer disease and implications for clinical care: systematic review. J Med Internet Res 2019, 21: e12785.Google Scholar
Kourtis, LC, Regele, OB, Wright, JM, Jones, GB. Digital biomarkers for Alzheimer’s disease: the mobile/wearable devices opportunity. NPJ Digit Med 2019; 2: 9.CrossRefGoogle ScholarPubMed
Piers, RJ, Devlin, KN, Ning, B, et al. Age and graphomotor decision making assessed with the digital clock drawing test: the Framingham Heart Study. J Alzheimers Dis 2017; 60: 1611–20.Google Scholar
Thomas, JA, Burkhardt, HA, Chaudhry, S, et al. Assessing the utility of language and voice biomarkers to predict cognitive impairment in the Framingham Heart Study cognitive aging cohort data. J Alzheimers Dis 2020; 76: 905–22.CrossRefGoogle ScholarPubMed
Moon, S, Song, HJ, Sharma, VD, et al. Classification of Parkinson’s disease and essential tremor based on balance and gait characteristics from wearable motion sensors via machine learning techniques: a data-driven approach. J Neuroeng Rehabil 2020; 17: 125.CrossRefGoogle ScholarPubMed
Leach, JM, Mancini, M, Kaye, JA, Hayes, TL, Horak, FB. Day-to-day variability of postural sway and its association with cognitive function in older adults: a pilot study. Front Aging Neurosci 2018; 10: 126.Google Scholar
Tulipani, LJ, Meyer, B, Larie, D, Solomon, AJ, McGinnis, RS. Metrics extracted from a single wearable sensor during sit–stand transitions relate to mobility impairment and fall risk in people with multiple sclerosis. Gait Post 2020; 80: 361–6.Google Scholar
Dorsey, ER, Omberg, L, Waddell, E. Deep phenotyping of Parkinson’s disease. J Parkinsons Dis 2020; 10: 855–73.Google Scholar
Hunfalvay, M, Roberts, CM, Murray, NP. Vertical smooth pursuit as a diagnostic marker of traumatic brain injury. Concussion 2020; 5: CNC69.Google Scholar
Regalia, G, Gerboni, G, Migliorini, M, et al. Sleep assessment by means of a wrist actigraphy-based algorithm: agreement with polysomnography in an ambulatory study on older adults. Chronobiol Int 2021; 38: 400–14.Google Scholar
Kuwabara, M, Harada, K, Hishiki, Y, Kario, K. Validation of two watch-type wearable blood pressure monitors according to the ANSI/AAMI/ISO81060-2:2013 guidelines: Omron HEM-6410 T-ZM and HEM-6410 T-ZL. J Clin Hypertens (Greenwich) 2019; 21: 853–8.Google Scholar
Collier, SR, McCraw, C, Campany, M, et al. Withings body cardio versus gold standards of pulse-wave velocity and body composition. J Pers Med 2020; 10: 17.Google Scholar
Mosnaim, GS, Stempel, DA, Gonzalez, C, et al. The impact of patient self-monitoring via electronic medication monitor and mobile app plus remote clinician feedback on adherence to inhaled corticosteroids: a randomized controlled trial. J Allergy Clin Immunol Pract 2021; 9: 1586–94.Google Scholar
Jafri, RZ, Balliro, CA, El-Khatib, F, A three-way accuracy comparison of the Dexcom G5, Abbott Freestyle Libre Pro, and Senseonics Eversense continuous glucose monitoring devices in a home-use study of subjects with type 1 diabetes. Diabetes Technol Therapeut 2020; 22: 846–52.Google Scholar
Vandenberk, T, Storms, V, Lanssens, D, et al. A vendor-independent mobile health monitoring platform for digital health studies: development and usability study. JMIR mHealth uHealth 2019; 7: e12586.CrossRefGoogle ScholarPubMed
Seelye, A, Mattek, N, Sharma, N. Weekly observations of online survey metadata obtained through home computer use allow for detection of changes in everyday cognition before transition to mild cognitive impairment. Alzheimers Dement 2018; 14: 187–94.Google Scholar
Sano, M, Zhu, CW, Kaye, J, et al. A randomized clinical trial to evaluate home-based assessment of people over 75 years old. Alzheimers Dement 2019; 15: 615–24.Google Scholar
Thomas, N, Beattie, Z, Marcoe, J, et al. An ecologically valid, longitudinal, and unbiased assessment of treatment efficacy in Alzheimer disease (the EVALUATE-AD trial): proof-of-concept study. JMIR Res Protoc 2020; 9: e17603.Google Scholar
Ahamed, F, Shahrestani, S, Cheung, H. Internet of things and machine learning for healthy ageing: identifying the early signs of dementia. Sensors (Basel) 2020; 20: E6031.Google Scholar
Cavuoto, MG, Kinsella, GJ, Ong, B, Pike, KE, Nicholas, CL. Naturalistic measurement of sleep in older adults with amnestic mild cognitive impairment: anxiety symptoms do not explain sleep disturbance. Curr Alzheimer Res 2019; 16: 233–42.Google Scholar
Øksnebjerg, L, Woods, B, Ruth, K, et al. A tablet app supporting self-management for people with dementia: explorative study of adoption and use patterns. JMIR mHealth uHealth 2020; 8: e14694.CrossRefGoogle ScholarPubMed
Buchman, AS, Dawe, RJ, Leurgans, SE. Different combinations of mobility metrics derived from a wearable sensor are associated with distinct health outcomes in older adults. J Gerontol A Biol Sci Med Sci 2020; 75: 1176–83.CrossRefGoogle ScholarPubMed
Mueller, A, Hoefling, HA, Muaremi, A, et al. Continuous digital monitoring of walking speed in frail elderly patients: noninterventional validation study and longitudinal clinical trial. JMIR mHealth uHealth 2019; 7: e15191.Google Scholar
De Vito, AN, Sawyer, RJ 2nd, LaRoche, A, et al. Acceptability and feasibility of a multicomponent telehealth care management program in older adults with advanced dementia in a residential memory care unit. Gerontol Geriatr Med 2020; 6: 2333721420924988.Google Scholar
Seelye, A, Leese, MI, Dorociak, K, et al. Feasibility of in-home sensor monitoring to detect mild cognitive impairment in aging military veterans: prospective observational study. JMIR Form Res 2020; 4: e16371.CrossRefGoogle ScholarPubMed
Lyons, BE, Austin, D, Seelye, A, et al. Pervasive computing technologies to continuously assess Alzheimer’s disease progression and intervention efficacy. Front Aging Neurosci 2015; 7: 102.Google ScholarPubMed
Dodge, HH, Zhu, J, Mattek, NC, et al. Use of high-frequency in-home monitoring data may reduce sample sizes needed in clinical trials. PloS One 2015; 10: e0138095.Google Scholar
Food and Drug Administration. Digital Health Center of Excellence. Available at: www.fda.gov/medical-devices/digital-health-center-excellence (accessed November 2020).Google Scholar
Xue, C, Karjadi, C, Paschalidis, IC, Au, R, Kolachalama, VB. Detection of dementia on voice recordings using deep learning: a Framingham Heart Study. Alzheimers Res Ther 2021; 13: 146.Google Scholar
Inan, OT, Tenaerts, P, Prindiville, SA, et al. Digitizing clinical trials. NPJ Digit Med 2020; 3: 1–7.Google Scholar
Steinhubl, SR, Wolff-Hughes, DL, Nilsen, W, Iturriaga, E, Califf, RM. Digital clinical trials: creating a vision for the future. NPJ Digit Med 2019; 2: 1–3.Google Scholar
National Academies of Sciences, Engineering, and Medicine. The Role of Digital Health Technologies in Drug Development: Proceedings of a Workshop. Washington, DC: The National Academies Press; 2020.Google Scholar